Wedbush Has Positive Forecast for BCRX Q4 Earnings

Key Points

• Wedbush has increased its Q4 2025 earnings estimate for BioCryst Pharmaceuticals to $0.05 per share, up from $0.04, and maintains an "Outperform" rating with a target price of $18.00.
• BioCryst recently reported Q2 earnings of $0.15 EPS, exceeding estimates, with a revenue increase of 49.5% year-over-year, highlighting strong business performance.
• Recent analyst ratings show a mixed outlook for BioCryst, with Zacks and Wall Street Zen upgrading their ratings to "strong-buy," while Weiss Ratings gave a "sell" rating.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at Wedbush boosted their Q4 2025 earnings estimates for BioCryst Pharmaceuticals in a research note issued on Tuesday, October 14th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $0.05 for the quarter, up from their prior estimate of $0.04. Wedbush has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q1 2026 earnings at $0.13 EPS, Q2 2026 earnings at $0.13 EPS, Q3 2026 earnings at $0.09 EPS and FY2028 earnings at $0.91 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The business's quarterly revenue was up 49.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.06) EPS.

A number of other analysts also recently issued reports on BCRX. Zacks Research raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, October 6th. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Royal Bank Of Canada restated an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Cantor Fitzgerald upped their price objective on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an "overweight" rating in a research report on Wednesday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $19.18.

BioCryst Pharmaceuticals Stock Up 6.1%

Shares of BioCryst Pharmaceuticals stock opened at $6.81 on Thursday. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -37.83, a price-to-earnings-growth ratio of 1.28 and a beta of 1.05. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31. The company has a 50-day simple moving average of $7.90 and a two-hundred day simple moving average of $8.65.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BCRX. Headlands Technologies LLC acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $32,000. GAMMA Investing LLC grew its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after buying an additional 5,449 shares during the last quarter. Family Legacy Financial Solutions LLC acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at about $72,000. New Age Alpha Advisors LLC acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $62,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $79,000. 85.88% of the stock is owned by institutional investors.

Insider Activity at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the transaction, the director directly owned 65,352 shares of the company's stock, valued at $556,145.52. This represents a 51.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.10% of the company's stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.